HighTower Advisors
CRDF icon

HighTower Advisors’s Cardiff Oncology CRDF Stock Holding History

HighTower Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.2K Buy
34,764
+598
+2% +$949 ﹤0.01% 3735
2026
Q1 		$55.3K Sell
34,166
-40
-0.1% -$82 ﹤0.01% 3696
2025
Q4 		$96.1K Hold
34,206
– – ﹤0.01% 3512
2025
Q3 		$70.5K Hold
34,206
– – ﹤0.01% 3586
2025
Q2 		$108K Sell
34,206
-7
-0% -$21 ﹤0.01% 3453
2025
Q1 		$107K Hold
34,213
– – ﹤0.01% 3345
2024
Q4 		$148K Buy
34,213
+18,880
+123% +$59K ﹤0.01% 3280
2024
Q3 		$41K Sell
15,333
-702
-4% -$1.66K ﹤0.01% 3429
2024
Q2 		$36K Sell
16,035
-1,965
-11% -$7.41K ﹤0.01% 3341
2024
Q1 		$96K Buy
18,000
+2,667
+17% +$7.09K ﹤0.01% 3159
2023
Q4 		$22K Hold
15,333
– – ﹤0.01% 3390
2023
Q3 		$21K Hold
15,333
– – ﹤0.01% 3323
2023
Q2 		$22K Hold
15,333
– – ﹤0.01% 3246
2023
Q1 		$25K Hold
15,333
– – ﹤0.01% 3125
2022
Q4 		$21K Hold
15,333
– – ﹤0.01% 3127
2022
Q3 		$23K Buy
+15,333
New +$36.9K ﹤0.01% 2958
2017
Q4 		– Sell
-354
Closed -$18K – 2296
2017
Q3 		$18K Sell
354
-557
-61% -$34.7K ﹤0.01% 2131
2017
Q2 		$84K Buy
911
+487
+115% +$31.4K ﹤0.01% 1990
2017
Q1 		$36K Sell
424
-1,041
-71% -$141K ﹤0.01% 1943
2016
Q4 		$223K Buy
1,465
+1,118
+322% +$261K ﹤0.01% 1627
2016
Q3 		$112K Sell
347
-327
-49% -$119K ﹤0.01% 1728
2016
Q2 		$219K Sell
674
-368
-35% -$127K ﹤0.01% 1454
2016
Q1 		$349K Buy
1,042
+695
+200% +$236K ﹤0.01% 1545
2015
Q4 		$135K Sell
347
-1,549
-82% -$607K ﹤0.01% 1816
2015
Q3 		$777K Buy
+1,896
New +$992K 0.01% 999

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HighTower Advisors's CRDF Position: Q2 2026 in Review

HighTower Advisors increased its Cardiff Oncology (CRDF) stake by 1.8% in Q2 2026, buying an estimated $949 and bringing the position to 34,764 shares worth $45.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3735.

HighTower Advisors first reported a position in CRDF in Q3 2015 and has held it in 25 quarters since. The position peaked at $777K in Q3 2015. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • HighTower Advisors held 34,764 shares of Cardiff Oncology worth $45.2K as of Q2 2026.
  • HighTower Advisors bought 598 Cardiff Oncology shares in Q2 2026, an estimated $949.
  • Cardiff Oncology made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3735 holding.
  • HighTower Advisors first reported a position in Cardiff Oncology in Q3 2015 and has held it in 25 quarters since.
  • HighTower Advisors's Cardiff Oncology position peaked at $777K in Q3 2015.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.